Phosphorylation of sst2 Receptors in Neuroendocrine Tumors after Octreotide Treatment of Patients

Somatostatin analogues, which are used to treat neuroendocrine tumors, target the high levels of somatostatin receptor subtype 2 (SSTR1; alias sst2) expressed in these cancers. However, some tumors are resistant to somatostatin analogues, and it is unknown whether the defect lies in sst2 activation...

Full description

Saved in:
Bibliographic Details
Main Authors: Waser, Beatrice, Cescato, Renzo, Liu, Qisheng, Kao, Yachu J., Körner, Meike, Christ, Emanuel, Schonbrunn, Agnes, Reubi, Jean Claude
Format: Artigo
Language:Inglês
Published: American Society for Investigative Pathology 2012
Subjects:
Regular Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3349840/
https://ncbi.nlm.nih.gov/pubmed/22538189
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ajpath.2012.01.041
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items